A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
Clinical trial NCT04126473 · COMPLETED
Trial details
- NCT number
- NCT04126473
- Sponsor
- Eloxx Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-05
- Primary completion
- 2022-04-06
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.